Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and initiatives.

Mirati's climate strategy is informed by the sustainability efforts of its parent company, Bristol-Myers Squibb. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Bristol-Myers Squibb. However, specific reduction targets or achievements for Mirati Therapeutics are not detailed in the available data.

As part of its corporate family, Mirati is aligned with industry-standard climate terminology and practices, although it has not set its own distinct reduction targets or climate pledges at this time. The company's commitment to sustainability is thus closely linked to the broader initiatives of Bristol-Myers Squibb, reflecting a collective approach to addressing climate change within the pharmaceutical sector.